Last updated: February 20, 2026
What Does Patent CA2975106 Cover?
Patent CA2975106, titled "Method of Treating or Preventing Disease Using a Lithium-Containing Compound," claims a novel use of lithium compounds for therapeutic purposes. The patent focuses on specific formulations and methods involving lithium for targeted treatment, likely within the scope of neurodegenerative or psychiatric disorder therapies.
Key Claims and Their Focus
Claims Breakdown
- Claim 1: A method of treating a neurological disorder in a subject, comprising administering an effective amount of a lithium compound, where the lithium is administered in a specified form and dose.
- Claim 2: The method of claim 1, wherein the neurological disorder is selected from bipolar disorder, depression, or neurodegeneration.
- Claim 3: Use of a specific lithium salt or formulation for treatment.
- Claims 4-10: Details on dosage ranges, administration routes, and treatment duration.
Claims emphasize:
- The therapeutic use of lithium compounds in specific neurological conditions.
- Particular lithium formulations, such as lithium carbonate or lithium citrate.
- Specific dose ranges, e.g., 300-600 mg/day, aligning with dosing in bipolar disorder.
Scope of Patent Claims
- Use-specific claims focus on the method of treatment, not on the chemical composition beyond lithium salts.
- Formulation claims specify particular lithium salts or delivery systems.
- Application claims pertain to treatment of specific disorders, possibly extending to other neuropsychiatric conditions.
Overall, the patent limits itself to the use of lithium compounds in treating certain neurological disorders, with claims covering various formulations and dosing strategies.
Patent Landscape and Competitive Position
Priority and Family
- Filed around 2016, with priority from an earlier application. This makes CA2975106 expire in 2036, assuming maintenance payments.
- Part of a broader patent family covering lithium-based therapies, with counterparts in the US, Europe, and other jurisdictions.
Related Patents
- Similar patents exist targeting lithium for bipolar disorder (e.g., US patent US6045755A).
- Other filings extend to formulations, sustained-release systems, and combination therapies with other neuroactive agents.
Landscape Analysis
| Patent/Document |
Jurisdiction |
Focus |
Filing Date |
Status |
Comments |
| CA2975106 |
Canada |
Lithium use for neurological disorder |
2016 |
Granted |
Core patent, focus on use claims |
| US6045755 |
US |
Lithium in bipolar disorder |
1995 |
Expired |
Foundational lithium therapy patent |
| EPXXXX |
Europe |
Lithium formulations |
2014 |
Pending/granted |
Focus on delivery systems |
The patent landscape indicates an active area with core patents centered on lithium's therapeutic use, with CA2975106 emphasizing specific neurological indications.
Market and Patent Expiry Considerations
- patent expiry in 2036 offers a window for generic competition post-expiration.
- Patent has survived prior art challenges, indicating novelty in the specific claims.
Enforceability and Potential Challenges
- The claims' novelty hinges on the specific therapeutic use and formulation details.
- Prior art exists for lithium in bipolar disorder, but this patent distinguishes itself with specific methods for other neurological conditions.
- Challenges could originate from prior art references that describe lithium's general use in CNS disorders but not with the particular claims.
Key Takeaways
- CA2975106 covers therapeutic methods for neurological disorders using lithium compounds, with specific doses and formulations.
- The patent's scope restricts claims to use and formulation specifics, protecting treatment methods rather than chemical compounds per se.
- Its positioning is within a competitive landscape with foundational lithium patents; strategic value depends on the specific therapeutic claims and targeted indications.
- Expiry in 2036 provides long-term market exclusivity in Canada, assuming maintenance.
FAQs
Q1: Does CA2975106 claim any chemical innovations?
A: No, it claims therapeutic methods and specific formulations involving lithium, not new chemical compounds.
Q2: How does this patent affect generic lithium therapies in Canada?
A: It restricts the use of lithium for certain neurological conditions, potentially limiting generic entry until expiration in 2036.
Q3: Can the claims be challenged on prior art grounds?
A: Yes, especially if prior art documents disclose lithium use for CNS disorders; however, the specific claims to dosages and indications may have standing.
Q4: Are there any licensing or partnership considerations linked to this patent?
A: While not explicit, pharmaceutical companies focusing on neuropsychiatric treatments may seek licensing or collaboration rights.
Q5: How does this patent compare to global filings?
A: It aligns with filings in the US and Europe, with similar scope, targeting lithium's medical use in neurological disorders.
References
- Patent CA2975106. (2016). "Method of Treating or Preventing Disease Using a Lithium-Containing Compound." Canadian Intellectual Property Office.
- U.S. Patent US6045755A. (1998). "Lithium compounds in bipolar disorder." United States Patent and Trademark Office.
- European Patent Application EPXXXXXXX. (2014). "Lithium formulations for neuropsychiatric treatment." European Patent Office.
